Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will join Benzinga's All Access Show for a 20-minute interview on September 17, 2021, at 10:10 am ET. Chairman Leonard Mazur will discuss advancements in the company's late-stage clinical pipeline, focusing on I/ONTAK (E7777), a novel oncology asset with potential for near-term revenue and a robust path toward commercial success. Citius is noted for its late-stage candidates, including Mino-Lok®, which is in a Phase 3 trial, and I/ONTAK, having completed enrollment in its pivotal Phase 3 trial.
- I/ONTAK (E7777) is highlighted as a novel oncology asset with a strong potential for commercial success.
- Citius has two late-stage product candidates, demonstrating progress in its clinical pipeline.
- Mino-Lok® is currently enrolling patients in a Phase 3 trial and has received Fast Track designation from the FDA.
- None.
CRANFORD, N.J., Sept. 14, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview on Friday, September 17, 2021 at 10:10 am ET.
Investors may tune in to the interview with Citius Chairman Leonard Mazur by visiting Benzinga's livestream channel.
During the interview, Mr. Mazur will discuss advancements in the Company's late-stage clinical pipeline, including the recent addition of I/ONTAK (E7777), a novel oncology asset with an attractive near-term revenue opportunity and substantially de-risked path to support commercial success.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok® was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Investor Relations for Citius Pharmaceuticals:
Ilanit Allen
Vice President, Corporate Communications and Investor Relations
T: 908-967-6677 x113
E: iallen@citiuspharma.com
View original content:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-join-benzinga-all-access-show-on-friday-september-17-2021-301376275.html
SOURCE Citius Pharmaceuticals, Inc.
FAQ
What date is Citius Pharmaceuticals appearing on Benzinga's All Access Show?
Who will represent Citius Pharmaceuticals in the interview?
What is the focus of the discussion during the Benzinga interview?
What clinical trials are Citius Pharmaceuticals currently conducting?
